Apr 7, 2013
HER2-positive breast cancer: Biomarker analysis identified women most likely to benefit from T-DM1
22, 2013. These findings were presented by Jos Baselga, M.D., Ph.D., physician-in-chief at Memorial Sloan-Kettering Cancer Center in New York, N.Y., at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. "EMILIA was a landmark phase III clinical trial," said Baselga.
Sorafenib With Gemcitabine or Capecitabine in Patients With HER-2...
To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.
Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta
Please enter my FDA Drug Approval Contest . It's a ton of fun. The more entries I get, the more data I have to crunch about sentiment for upcoming drug approvals that I can share with you.
FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), the...
Genentech, a member of the Roche Group , today announced that the U.S. Food and Drug Administration has approved Kadcyla for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin and a taxane chemotherapy.
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team
CAMBRIDGE, Mass. & LAUSANNE, Switzerland -- -- ARIAD Pharmaceuticals, Inc. today announced the appointment of Jonathan E. Dickinson to the position of General Manager, ARIAD Pharmaceuticals , Sarl.